Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists
Graphical abstract
References and notes (17)
- et al.
Trends Cell Bio.
(2008)et al.Nature Rev. Mol. Cell Biol.
(2008)et al.Oncogene
(2010)et al.Nature Rev. Mol. Cell Bio.
(2010) - et al.
J. Med. Chem.
(2010) - et al.
Drug Discov. Today
(2010) - et al.
Curr. Opin. Chem. Biol.
(2010) - et al.
Cell Death Differ.
(2009) - et al.
J. Med. Chem.
(2007)et al.J. Med. Chem.
(2008) - et al.
Cancer Res.
(2008)et al.Cancer Chemother. Phamacol.
(2010) - et al.
Clin. Cancer Res.
(2010)
Cited by (23)
Copper-Catalyzed N,N-Alkyl Formylation of Sulfonamides
2023, Asian Journal of Organic ChemistryPharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy
2021, Bioorganic ChemistryCitation Excerpt :A dose-dependent decrease in the expression of phosphorylated Bcl-2 was observed in comparison with control cells (66% at the IC50 concentration or 80% at ½ IC50 concentration as compared to 90% in control) (Fig. 8). Interestingly, pyrazoline-based agents demonstrate substantial Bcl-2 inhibition [108–112], and, our previously reported diaryl pyrazoline and pyrrolidine-2,5-dione hybrid S2 has also shown significant reduction of Bcl-2 expression [19], thus, we can assume that it is one of the key factors responsible for inducing apoptotic cell death and cytotoxicity of compound H13. Furthermore, to understand this better, we performed molecular docking studies (see below) which demonstrated fitting of H13 in the sub-pocket of Bcl-2 (Fig. 9).
Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1
2018, Computational Biology and ChemistryRational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL
2017, Organic and Biomolecular ChemistryDynamics of the BH3-Only Protein Binding Interface of Bcl-xL
2015, Biophysical JournalCitation Excerpt :Such intrinsic interfacial conformational dynamics could provide a physical basis that enables Bcl-xL to respond sensitively to the nature of the bound ligand and/or environmental conditions, thus allowing facile unfolding upon specific binding of appropriate ligands such as PUMA. A total of 45 PDB entries were identified that contain either unbound Bcl-xL monomer or its complex with small molecule or peptide ligands (as of September 2014) (18,28,34–54). Four domain-swapped dimers of Bcl-xL, namely, 3FDL, 2YQ6, 2YQ7, and 4A1U, are also included, where α1 is involved in intermolecular interactions and adopts a very different configuration (e.g., see Fig. S1 in the Supporting Material).
Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists
2012, Bioorganic and Medicinal Chemistry Letters
- †
Authors contributed equally to the composition of this manuscript.
- ‡
Current address: PharmaResources (Shanghai) Co., Ltd, Building 1B, No. 528 RuiQing Rd., Pudong, Shanghai 201201, PR China.
- §
Current address: Hoffman-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.